Stoke Therapeutics, Inc. (STOK) Net Income (Loss) Attributable to Parent USD 2018 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Stoke Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2018 to 2024.
  • Stoke Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending March 31, 2024 was -$26.4 M, a 17% decline year-over-year.
  • Stoke Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending March 31, 2024 was -$109 M, a 9.67% decline year-over-year.
  • Stoke Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$105 M, a 3.59% decline from 2022.
  • Stoke Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$101 M, a 17.8% decline from 2021.
  • Stoke Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$85.8 M, a 64.2% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$109 M -$26.4 M -$3.83 M -17% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-06
Q4 2023 -$105 M -$27 M -$1.3 M -5.08% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-25
Q3 2023 -$103 M -$24.5 M +$1.57 M +6.01% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-07
Q2 2023 -$105 M -$30.7 M -$6 M -24.3% Apr 1, 2023 Jun 30, 2023 10-Q 2023-11-07
Q1 2023 -$99 M -$22.5 M +$2.1 M +8.54% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-06
Q4 2022 -$101 M -$25.7 M -$1.21 M -4.94% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-25
Q3 2022 -$99.9 M -$26.1 M -$3.51 M -15.6% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 -$96.3 M -$24.7 M -$2.69 M -12.2% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-07
Q1 2022 -$93.7 M -$24.6 M -$7.86 M -46.8% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-07
Q4 2021 -$85.8 M -$24.4 M -$9.89 M -67.9% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-06
Q3 2021 -$75.9 M -$22.6 M -$8.91 M -65.1% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$67 M -$22 M -$9.01 M -69.5% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-14
Q1 2021 -$58 M -$16.8 M -$5.75 M -52.1% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-14
Q4 2020 -$52.2 M -$14.6 M -$4.4 M -43.3% Oct 1, 2020 Dec 31, 2020 10-K 2021-03-09
Q3 2020 -$47.8 M -$13.7 M -$5.08 M -59% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-08
Q2 2020 -$42.8 M -$13 M -$5.14 M -65.7% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-08
Q1 2020 -$37.6 M -$11 M -$5.3 M -92.3% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-08
Q4 2019 -$32.3 M -$10.2 M -$5.88 M -137% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-09
Q3 2019 -$26.4 M -$8.6 M -$5.29 M -159% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-09
Q2 2019 -$21.2 M -$7.82 M -$4.81 M -160% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-09
Q1 2019 -$16.4 M -$5.74 M -$3.83 M -200% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-09
Q4 2018 -$12.5 M -$4.28 M Oct 1, 2018 Dec 31, 2018 10-K 2020-03-23
Q3 2018 -$3.32 M Jul 1, 2018 Sep 30, 2018 10-K 2020-03-23
Q2 2018 -$3.01 M Apr 1, 2018 Jun 30, 2018 10-K 2020-03-23
Q1 2018 -$1.91 M Jan 1, 2018 Mar 31, 2018 10-K 2020-03-23
* An asterisk sign (*) next to the value indicates that the value is likely invalid.